PeptiDream Inc. (TYO: 4587)
Japan
· Delayed Price · Currency is JPY | Market Cap | 273.87B |
| Revenue (ttm) | 47.77B |
| Net Income (ttm) | 17.11B |
| Shares Out | 129.61M |
| EPS (ttm) | 131.87 |
| PE Ratio | 16.02 |
| Forward PE | 22.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 751,700 |
| Average Volume | 805,045 |
| Open | 2,134.00 |
| Previous Close | 2,113.00 |
| Day's Range | 2,117.00 - 2,188.50 |
| 52-Week Range | 1,224.50 - 3,060.00 |
| Beta | 0.54 |
| RSI | 21.36 |
| Earnings Date | Feb 13, 2025 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates... [Read more]
Financial Performance
In 2023, PeptiDream's revenue was 28.71 billion, an increase of 6.93% compared to the previous year's 26.85 billion. Earnings were 3.04 billion, a decrease of -59.82%.
Financial StatementsNews
PeptiDream: Opulent Dream Now A Reality
PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.